OBJECTIVES: To use a non-biased assay for circulating tumour cells (CTCs) in patients with prostate cancer (PCa) in order to identify non-traditional CTC phenotypes potentially excluded by conventional detection methods that are reliant on antigen- and/or size-based enrichment. PATIENTS AND METHODS: A total of 41 patients with metastatic castration-resistant PCa (mCRPC) and 20 healthy volunteers were analysed on the Epic CTC platform, via high-throughput imaging of DAPI expression and CD45/cytokeratin (CK) immunofluorescence (IF) on all circulating nucleated cells plated on glass slides. To confirm the PCa origin of CTCs, IF was used for androgen receptor (AR) expression and fluorescence in situ hybridization was used for PTEN and ERG assessment. RESULTS: Traditional CTCs (CD45- /CK+ /morphologically distinct) were identified in all patients with mCRPC and we also identified CTC clusters and non-traditional CTCs in patients with mCRPC, including CK- and apoptotic CTCs. Small CTCs (≤white blood cell size) were identified in 98% of patients with mCRPC. Total, traditional and non-traditional CTCs were significantly increased in patients who were deceased vs alive after 18 months; however, only non-traditional CTCs were associated with overall survival. Traditional and total CTC counts according to the Epic platform in the mCRPC cohort were also significantly correlated with CTC counts according to the CellSearch system. CONCLUSIONS: Heterogeneous non-traditional CTC populations are frequent in mCRPC and may provide additional prognostic or predictive information.
OBJECTIVES: To use a non-biased assay for circulating tumour cells (CTCs) in patients with prostate cancer (PCa) in order to identify non-traditional CTC phenotypes potentially excluded by conventional detection methods that are reliant on antigen- and/or size-based enrichment. PATIENTS AND METHODS: A total of 41 patients with metastatic castration-resistant PCa (mCRPC) and 20 healthy volunteers were analysed on the Epic CTC platform, via high-throughput imaging of DAPI expression and CD45/cytokeratin (CK) immunofluorescence (IF) on all circulating nucleated cells plated on glass slides. To confirm the PCa origin of CTCs, IF was used for androgen receptor (AR) expression and fluorescence in situ hybridization was used for PTEN and ERG assessment. RESULTS: Traditional CTCs (CD45- /CK+ /morphologically distinct) were identified in all patients with mCRPC and we also identified CTC clusters and non-traditional CTCs in patients with mCRPC, including CK- and apoptotic CTCs. Small CTCs (≤white blood cell size) were identified in 98% of patients with mCRPC. Total, traditional and non-traditional CTCs were significantly increased in patients who were deceased vs alive after 18 months; however, only non-traditional CTCs were associated with overall survival. Traditional and total CTC counts according to the Epic platform in the mCRPC cohort were also significantly correlated with CTC counts according to the CellSearch system. CONCLUSIONS: Heterogeneous non-traditional CTC populations are frequent in mCRPC and may provide additional prognostic or predictive information.
Authors: Matthew G Krebs; Robert L Metcalf; Louise Carter; Ged Brady; Fiona H Blackhall; Caroline Dive Journal: Nat Rev Clin Oncol Date: 2014-01-21 Impact factor: 66.675
Authors: Dena Marrinucci; Kelly Bethel; Richard H Bruce; Douglas N Curry; Ben Hsieh; Mark Humphrey; Robert T Krivacic; Joan Kroener; Lindsay Kroener; Andras Ladanyi; Nicole H Lazarus; Jorge Nieva; Peter Kuhn Journal: Hum Pathol Date: 2006-12-22 Impact factor: 3.466
Authors: Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; Jeri Matera; M Craig Miller; James M Reuben; Gerald V Doyle; W Jeffrey Allard; Leon W M M Terstappen; Daniel F Hayes Journal: N Engl J Med Date: 2004-08-19 Impact factor: 91.245
Authors: H Ben Hsieh; Dena Marrinucci; Kelly Bethel; Douglas N Curry; Mark Humphrey; Robert T Krivacic; Joan Kroener; Lindsay Kroener; Andras Ladanyi; Nicole Lazarus; Peter Kuhn; Richard H Bruce; Jorge Nieva Journal: Biosens Bioelectron Date: 2006-02-07 Impact factor: 10.618
Authors: Lixin Zhang; Lon D Ridgway; Michael D Wetzel; Jason Ngo; Wei Yin; Disha Kumar; Jerry C Goodman; Morris D Groves; Dario Marchetti Journal: Sci Transl Med Date: 2013-04-10 Impact factor: 17.956
Authors: Christopher Foster; Douglas Easton; Ultan McDermott; David C Wedge; G Steven Bova; Gunes Gundem; Peter Van Loo; Barbara Kremeyer; Ludmil B Alexandrov; Jose M C Tubio; Elli Papaemmanuil; Daniel S Brewer; Heini M L Kallio; Gunilla Högnäs; Matti Annala; Kati Kivinummi; Victoria Goody; Calli Latimer; Sarah O'Meara; Kevin J Dawson; William Isaacs; Michael R Emmert-Buck; Matti Nykter; Zsofia Kote-Jarai; Hayley C Whitaker; David E Neal; Colin S Cooper; Rosalind A Eeles; Tapio Visakorpi; Peter J Campbell Journal: Nature Date: 2015-04-01 Impact factor: 49.962
Authors: Elan Diamond; Guang Yu Lee; Naveed H Akhtar; Brian J Kirby; Paraskevi Giannakakou; Scott T Tagawa; David M Nanus Journal: Front Oncol Date: 2012-10-11 Impact factor: 6.244
Authors: Howard I Scher; Ryon P Graf; Nicole A Schreiber; Anuradha Jayaram; Eric Winquist; Brigit McLaughlin; David Lu; Martin Fleisher; Sarah Orr; Lori Lowes; Amanda Anderson; Yipeng Wang; Ryan Dittamore; Alison L Allan; Gerhardt Attard; Glenn Heller Journal: JAMA Oncol Date: 2018-09-01 Impact factor: 31.777
Authors: Emma E van der Toom; Haley D Axelrod; Jean J de la Rosette; Theo M de Reijke; Kenneth J Pienta; Kenneth C Valkenburg Journal: Nat Rev Urol Date: 2019-01 Impact factor: 14.432
Authors: Howard I Scher; Ryon P Graf; Nicole A Schreiber; Brigit McLaughlin; Adam Jendrisak; Yipeng Wang; Jerry Lee; Stephanie Greene; Rachel Krupa; David Lu; Pascal Bamford; Jessica E Louw; Lyndsey Dugan; Hebert A Vargas; Martin Fleisher; Mark Landers; Glenn Heller; Ryan Dittamore Journal: Cancer Res Date: 2017-08-17 Impact factor: 12.701
Authors: Udit Singhal; Yugang Wang; James Henderson; Yashar S Niknafs; Yuanyuan Qiao; Amy Gursky; Alexander Zaslavsky; Jae-Seung Chung; David C Smith; R Jeffrey Karnes; S Laura Chang; Felix Y Feng; Ganesh S Palapattu; Russell S Taichman; Arul M Chinnaiyan; Scott A Tomlins; Todd M Morgan Journal: Mol Cancer Res Date: 2018-02-16 Impact factor: 5.852